[go: up one dir, main page]

CL2021001235A1 - Anticuerpos anti-nkg2a y usos de los mismos - Google Patents

Anticuerpos anti-nkg2a y usos de los mismos

Info

Publication number
CL2021001235A1
CL2021001235A1 CL2021001235A CL2021001235A CL2021001235A1 CL 2021001235 A1 CL2021001235 A1 CL 2021001235A1 CL 2021001235 A CL2021001235 A CL 2021001235A CL 2021001235 A CL2021001235 A CL 2021001235A CL 2021001235 A1 CL2021001235 A1 CL 2021001235A1
Authority
CL
Chile
Prior art keywords
antibodies
nkg2a
cancer
present disclosure
monoclonal antibodies
Prior art date
Application number
CL2021001235A
Other languages
English (en)
Inventor
Natalie Bezman
Alan J Korman
Shrikant Deshpande
Amy D Jhatakia
Richard Y Huang
Guodong Chen
Ginger C Rakestraw
Karla Ann Henning
Vangipuram S Rangan
Christine BEE
Xiang Shao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68835343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021001235(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2021001235A1 publication Critical patent/CL2021001235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)

Abstract

La presente descripción proporciona anticuerpos monoclonales aislados (por ejemplo, anticuerpos monoclonales humanizados y humanos), o fragmentos de unión a antígeno de los mismos, que se unen específicamente a la proteína del receptor inhibidor de la célula asesina natural humana del grupo 2A (NKG2A) con alta afinidad y exhiben propiedades funcionales terapéuticamente deseables, para el tratamiento de, por ejemplo, cáncer. También se proporcionan inmunoconjugados, moléculas biespecíficas y composiciones farmacéuticas que comprenden los anticuerpos anti-NKG2A de la invención. Se proporcionan además moléculas de ácido nucleico que codifican los anticuerpos, vectores de expresión, células hospederas y métodos de tratamiento de, por ejemplo, cáncer que utilizan los anticuerpos. La terapia de combinación, en la que un anticuerpo anti-NKG2A en la presente descripción se administra conjuntamente con al menos un agente adicional tal como otro anticuerpo (por ejemplo, anticuerpos anti-PD-1, anti-PD-L1 y/o anti-CTLA- 4), también se proporciona.
CL2021001235A 2018-11-16 2021-05-11 Anticuerpos anti-nkg2a y usos de los mismos CL2021001235A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862768471P 2018-11-16 2018-11-16
US201962927211P 2019-10-29 2019-10-29

Publications (1)

Publication Number Publication Date
CL2021001235A1 true CL2021001235A1 (es) 2021-10-15

Family

ID=68835343

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001235A CL2021001235A1 (es) 2018-11-16 2021-05-11 Anticuerpos anti-nkg2a y usos de los mismos

Country Status (17)

Country Link
US (4) US11274150B2 (es)
EP (1) EP3880708A1 (es)
JP (3) JP7520003B2 (es)
KR (1) KR20210092769A (es)
CN (1) CN113316590B (es)
AU (1) AU2019380307B2 (es)
BR (1) BR112021009111A2 (es)
CL (1) CL2021001235A1 (es)
CO (1) CO2021006248A2 (es)
IL (1) IL282968A (es)
MX (1) MX2021005708A (es)
MY (1) MY205758A (es)
NZ (1) NZ777032A (es)
PE (1) PE20211284A1 (es)
SG (1) SG11202104969RA (es)
TW (1) TW202033555A (es)
WO (1) WO2020102501A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013978A (es) * 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
EP4196502A1 (en) 2020-08-13 2023-06-21 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
HRP20250628T1 (hr) 2020-12-28 2025-07-18 Bristol-Myers Squibb Company Mješavine antitijela i postupci njihove upotrebe
KR20240016991A (ko) 2021-06-01 2024-02-06 르 라보레또레 쎄르비에르 항-nkg2a 항체 및 조성물
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
JP2024537840A (ja) * 2021-10-04 2024-10-16 レ ラボラトワール セルヴィエ Ｎｋｇ２ａを標的化する癌療法
CN116136491A (zh) * 2021-11-18 2023-05-19 中山康方生物医药有限公司 检测抗cd47抗体的装置和检测方法
JP2025500845A (ja) * 2021-12-14 2025-01-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子
CN118574853A (zh) * 2022-01-24 2024-08-30 恺兴生命科技(上海)有限公司 Nkg2a抗体及其应用
JP2025523846A (ja) 2022-07-11 2025-07-25 ジェヌーヴ インク． サイトカイン融合タンパク質
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024056010A1 (zh) * 2022-09-16 2024-03-21 北京三诺佳邑生物技术有限责任公司 特异性识别nkg2a的抗体及其应用
CN115957319B (zh) * 2022-10-14 2023-06-30 北京东方百泰生物科技股份有限公司 一种抗nkg2a单克隆抗体的注射制剂
GB202216284D0 (en) * 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation
CN115820645B (zh) * 2022-11-28 2023-09-22 上海恩凯细胞技术有限公司 制备沉默nkg2a基因的nk细胞的方法及其用途
KR102542075B1 (ko) * 2022-12-05 2023-06-15 넥스탭 주식회사 Klrc1 단백질을 표적으로 하는 인터페론-γ 조절 물질의 확인방법 및 이 물질을 포함하는 의약
CN118203672A (zh) * 2022-12-15 2024-06-18 广东粤港澳大湾区国家纳米科技创新研究院 类三特异性抗体药物制剂及其制备方法和应用
WO2025168052A1 (en) * 2024-02-08 2025-08-14 Hanx Biopharmaceuticals, (Wuhan) Ltd. Nkg2a/cd94-targeting antibodies and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025225645A1 (ja) * 2024-04-24 2025-10-30 第一三共株式会社 Ｎｋｇ２ａアゴニストを用いた免疫拒絶の回避方法
WO2026001907A1 (en) * 2024-06-24 2026-01-02 Elpiscience (Suzhou) Biopharma, Ltd. Anti-nkg2a antibodies, fusion proteins and uses thereof
CN121108342A (zh) * 2025-09-08 2025-12-12 北京明璨生物科技有限公司 Nk细胞的制备方法及其在治疗癌症中的用途

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
JPH06506358A (ja) 1991-03-28 1994-07-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ ナチュラルキラー細胞に特異的なｄｎａおよびアミノ酸配列
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
HRP20010551B1 (hr) 1998-12-23 2013-05-31 Pfizer Inc. Humana monoklonalna antitijela za ctla-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
HU228477B1 (en) 1999-08-23 2013-03-28 Dana Farber Cancer Inst Inc Pd-1, a receptor for b7-4, and uses therefor
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US8993319B2 (en) 2004-12-28 2015-03-31 Innate Pharma S.A. Monoclonal antibodies against NKG2A
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
KR101304157B1 (ko) 2005-06-16 2013-09-06 넥타르 테라퓨틱스 분해가능한 결합을 갖는 컨주게이트 및 이러한 컨주게이트제조에 유용한 고분자 시약
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
US8815237B2 (en) 2007-12-05 2014-08-26 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2356131A4 (en) 2008-12-08 2012-09-12 Tegopharm Corp MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
HUE026201T2 (en) 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies binding to human CSF1R extracellular domain 4 and their use
SG181477A1 (en) 2009-12-10 2012-07-30 Regeneron Pharma Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
SG185035A1 (en) 2010-05-04 2012-11-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
PL2480676T3 (pl) 2010-06-22 2016-10-31 Mysz wykazująca ekspresję hybrydowego łańcucha lekkiego immunoglobuliny
DK2637694T3 (da) 2010-11-12 2021-06-07 Nektar Therapeutics KONJUGATER AF EN Il-2-ENHED OG EN POLYMER
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
NO2694640T3 (es) 2011-04-15 2018-03-17
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
EA201892339A3 (ru) 2011-12-19 2019-06-28 Дзе Рокфеллер Юниверсити Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
JP2015519375A (ja) 2012-05-31 2015-07-09 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−ｌ１に結合する抗原結合蛋白質
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SI3835310T1 (sl) 2012-09-13 2024-07-31 Bristol-Myers Squibb Company Proteini skafold domene na osnovi fibronektina, ki se vežejo na miostatin
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
WO2015035606A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3134123B1 (en) 2014-02-21 2021-02-17 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody
SG11201701385WA (en) 2014-08-28 2017-03-30 Academisch Ziekenhuis Leiden Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
US10711063B2 (en) 2014-09-16 2020-07-14 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR20240141862A (ko) 2014-09-16 2024-09-27 이나뜨 파르마 에스.에이. 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
ES2881484T3 (es) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anticuerpos anti-PD-1
SG10201913297TA (en) 2015-03-13 2020-02-27 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
KR20180101417A (ko) 2016-01-11 2018-09-12 아르모 바이오사이언시스 인코포레이티드 항원-특이적 cd8+ t 세포의 제조에서 인터루킨-10 및 이의 사용 방법
EP3868787A1 (en) * 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017132825A1 (zh) 2016-02-02 2017-08-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
CA3033542A1 (en) 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3765508A1 (en) 2018-03-13 2021-01-20 Innate Pharma Treatment of head and neck cancer
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof

Also Published As

Publication number Publication date
JP7623462B2 (ja) 2025-01-28
IL282968A (en) 2021-06-30
AU2019380307A1 (en) 2021-07-01
NZ777032A (en) 2024-07-26
CA3119838A1 (en) 2020-05-22
SG11202104969RA (en) 2021-06-29
JP2025081301A (ja) 2025-05-27
CN113316590B (zh) 2025-02-28
TW202033555A (zh) 2020-09-16
US12077584B2 (en) 2024-09-03
AU2019380307B2 (en) 2026-01-29
EP3880708A1 (en) 2021-09-22
MY205758A (en) 2024-11-12
US20250101100A1 (en) 2025-03-27
KR20210092769A (ko) 2021-07-26
US20220204618A1 (en) 2022-06-30
US11981734B2 (en) 2024-05-14
JP7520003B2 (ja) 2024-07-22
JP2022509942A (ja) 2022-01-25
BR112021009111A2 (pt) 2021-08-24
PE20211284A1 (es) 2021-07-19
US11274150B2 (en) 2022-03-15
CO2021006248A2 (es) 2021-05-31
US20220195042A1 (en) 2022-06-23
JP2024037894A (ja) 2024-03-19
US20200199226A1 (en) 2020-06-25
WO2020102501A1 (en) 2020-05-22
MX2021005708A (es) 2021-09-21
CN113316590A (zh) 2021-08-27

Similar Documents

Publication Publication Date Title
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
MX2020008795A (es) Anti cuerpos anti tigit y usos de los mismos.
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
ECSP19010852A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso
MX2019003326A (es) Anticuerpos anti-muc16-cd3 biespecificos y conjugados anti-muc16-farmaco.
PE20180795A1 (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
PE20191813A1 (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno
MX2017005976A (es) Moleculas de union especificas para grupo de diferenciacion 73 (cd73) y usos de las mismas.
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112018011336A2 (pt) anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
MX376973B (es) Anticuerpos anti-ceacam6 y sus usos.
AR087615A1 (es) Moleculas biespecificas de union a antigeno
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
MX2020012081A (es) Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
AR126253A2 (es) Moléculas de unión al antígeno y métodos de uso
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2020006155A (es) Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
EA202092122A1 (ru) Антитела против tip-1 и их применения